Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

ids and HbA1c and, in the BLOOM-DM trial, other indicators of glycemic control will also be evaluated. In both of these additional studies, all patients will receive echocardiograms at baseline, at month 6, and at the end of the study to assess heart valve function over time. In contrast to the ongoing BLOOM trial, however, there will be no independent monitoring by an Echocardiographic Safety Monitoring Board. The complete lorcaserin Phase 3 pivotal program is planned to enroll a total of approximately 7,000 patients in these three trials. In addition to the planned pivotal trial program, several additional small studies, such as drug interaction and abuse potential studies, will be conducted.

"As we continue advancing our lorcaserin clinical program, we are looking forward to March 2008 when we expect the BLOOM Echocardiographic Safety Monitoring Board's review of echocardiograms for patients completing 12 months of treatment. We will continue to work with the FDA as we implement the final non-pivotal trial elements of the complete Phase 3 program," stated William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer.

An earlier estimate of the total external clinical costs of the Phase 3 trial program was updated from approximately $125 million to approximately $160 million. The increased estimate is primarily due to the increased number of patients Arena plans to enroll, and to Arena's initiative to expand the echocardiographic monitoring program by including patients with FDA-defined valvulopathy in the BLOSSOM and BLOOM-DM trials.

About Lorcaserin

Lorcaserin, Arena's internally discovered oral drug candidate for the treatment of obesity, is in an ongoing Phase 3 program. The compound stimulates the 5-HT2C serotonin receptor, located in the hypothalamus, an area of the brain associated with the control of satiety and metabolism. Results from Phase 2 studies demonstrated that treatment with lorcaserin produced highly sta
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... dental biomaterial market will grow moderately through 2023 as ... and growing awareness of dental biomaterials all spur procedure ... such as China and ... bring dental procedures within reach for a larger proportion ...
(Date:12/19/2014)... DALLAS , Dec. 18, 2014   ISN ... Health & Safety Performance Indicators publication series. ... hours of activity reported in 2013 within its online ... health and safety key performance indicator (KPI) statistics. ... Hiring Clients, U.S. publication is available in ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... (PRWEB) December 16, 2014 “Never ... at Philipps- Universität Marburg’s Department of Physics, advises ... in the newly released SPIE Women in ... be too shy to ask questions.” , In ... engineering, and mathematics) occupations ranging from university professor ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... MADISON, Wis., Sept. 8 From the transfection experts, Mirus Bio ... , , Mirus has expanded its transfection expertise ... transfection reagent which offers users: , , ... and Lipofectamine(TM) 2000 CD in many cell types. , ...
... , , , CAMBRIDGE, ... VRNM ), a pioneer in the development of next-generation ... previously announced 1-for-12 reverse stock split of the Company,s common ... 9, 2009. Verenium,s shares will continue to trade on ...
... , , $5 ... Western PA Companies , , HARRISBURG, ... will be able to expand and create quality jobs with the ... Rendell said today. , , "The life sciences ...
Cached Biology Technology:Verenium Announces Reverse Stock Split to Take Effect September 9 2Verenium Announces Reverse Stock Split to Take Effect September 9 3Verenium Announces Reverse Stock Split to Take Effect September 9 4PA Helping Life Science Companies Secure Venture Capital Needed to Expand, Gov. Rendell Says 2
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... of the Dog in the Twentieth Century, will include an exploration ... dogs that are pure bred, which three years ago resulted in ... concerns about the health of pedigree dogs. "It is a ... modern position as a domestic companion and use in various types ...
... the world,s preeminent gastroenterologists have convened this week ... Annual Scientific Meeting at the Gaylord National Hotel ... to review the latest scientific advances in gastrointestinal ... management. Groundbreaking treatments such as fecal microbiota ...
... An international team of researchers led by investigators in the U.S. ... endocycle, a common cell cycle that fuels growth in plants, animals ... half of the Earth,s biomass. This discovery, led by a geneticist ... Nature , leads to a new understanding of how cells ...
Cached Biology News:It's a dog's life: $800,000 study launched into man's best friend 2New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 2New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 3New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 4New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 5New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 6New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 7New research on GI health unveiled at American College of Gastroenterology's 2011 Meeting 8Research team clarifies mechanics of first new cell cycle to be described in more than 20 years 2Research team clarifies mechanics of first new cell cycle to be described in more than 20 years 3
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
...
... of robotic workstations is designed for laboratories ... the ideal automation platform for routine sample ... procedures, improving throughput, process consistency and safety. ... software allows you to control the robotic ...
...
Biology Products: